Ischemic Stroke Clinical Trial
Official title:
Head Position in Stroke Trial
A simplest manner to augment cerebral blood flow to irrigate the ischemic penumbra in acute
ischemic stroke could be to place the patient in a 'lying flat' rather than upright head
position. Given uncertainty over the balance of potential modest benefits and risks, and
variability regarding the ideal head position policy for patients with acute ischemic stroke
around the world, reliable randomized evidence is required to standardize clinical practice.
The main objectives of this pilot phase clinical trial are to determine the feasibility,
safety and potential efficacy of a large-scale cluster randomized clinical trial to assess
whether a simple nursing care policy - 'lying flat head position' - provides beneficial
effects as compared to the standard upright head position in patients with acute ischemic
stroke. The main efficacy outcome of the pilot phase is demonstration of increased mean
cerebral blood flow velocity in the flat down compared to the upright head position, as
assessed by transcranial Doppler to the medial cerebral arteries of patients with anterior
circulation infarction. Secondary efficacy objectives are to demonstrate that the flat down
head position improves neurological status at 7 days and disability at 90 days.
Background: Several lines of investigation indicate there to be potential beneficial effects
of interventions that augment cerebral blood flow (CBF) to irrigate the ischemic penumbra in
acute ischemic stroke. The simplest manner to do this is to place the patient in a 'lying
flat' rather than upright head position. However, any potential benefits on the brain may be
offset by an increased hazard of aspiration pneumonia or exacerbation of cardiac failure in
vulnerable patients. Given uncertainty over the balance of potential modest benefits and
risks, and variability regarding the ideal head position policy for patients with acute
ischemic stroke around the world, reliable randomized evidence is required to standardize
clinical practice.
Aims: The main objectives of this pilot phase clinical trial are to determine the
feasibility, safety and potential efficacy of a large-scale cluster randomized clinical
trial to assess whether a simple nursing care policy - 'lying flat head position' - provides
beneficial effects as compared to the standard upright head position in patients with acute
ischemic stroke. The main efficacy outcome of the pilot phase is demonstration of increased
mean cerebral blood flow velocity (CBFV) in the lying flat head position compared to the
upright head position, as assessed by transcranial Doppler (TCD) to the medial cerebral
arteries of patients with anterior circulation infarction. Secondary efficacy objectives are
to demonstrate that the lying flat head position improves neurological status at 7 days and
disability at 90 days.
Methods: Inclusion criteria include consecutive adult patients with acute ischemic stroke
within 12 hours of onset admitted to participating centers. A cluster (month) method of
randomization to lying flat or upright head position for 48 hours, stratified by site The
primary outcome is change in mean CBFV measured by TCD at 24 hours. Secondary outcomes
include proportion of adverse events at 7 days, distribution of NIHSS at 7 days, and
distribution of mRS disability scale scores at 90 days. Sample size is 46 clusters of 2
patients totaling approximately 92 patients to detect an increase of 8.31 (CI 95% 4.82-12.0)
cm/sec in average CBFV from 30° to 0° head position. This sample size will also allow
detection of that difference with 90% power at a 5% significance level, considering an ICC
of 0.037.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
| Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
| Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
| Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
| Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
| Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
| Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
| Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
| Not yet recruiting |
NCT06462599 -
Osteopontin Gene Polymorphism in Stroke Patients in Egypt
|
||
| Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
| Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
| Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
| Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
| Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
| Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
| Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
| Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
| Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
| Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 |